Cambridge researchers awarded the Millennium Technology Prize
British duo Professor Shankar Balasubramanian and Professor David Klenerman have been awarded the Millennium Technology Prize for their development of revolutionary DNA sequencing techniques.
University of Cambridge chemists Shankar Balasubramanian and David Klenerman have been jointly awarded the 2020 Millennium Technology Prize, one of the world’s most prestigious science and technology prizes, by Technology Academy Finland (TAF).
The global prize, awarded at two-year intervals since 2004 to highlight the impact of science and innovation on society, is worth €1 million. Of the nine previous winners of the Millennium Technology Prize, three have subsequently gone on to win a Nobel Prize. This is the first time that the prize has been awarded to more than one recipient for the same innovation, celebrating the significance of collaboration. The announcement of the 2020 award was delayed due to the COVID-19 pandemic.
Professors Balasubramanian and Klenerman co-invented Solexa-Illumina Next Generation DNA Sequencing (NGS), technology that has enhanced our basic understanding of life, converting biosciences into ‘big science’ by enabling fast, accurate, low-cost and large-scale genome sequencing – the process of determining the complete DNA sequence of an organism’s make-up. They co-founded the company Solexa to make the technology available to the world.
The technology has had – and continues to have – a transformative impact in the fields of genomics, medicine and biology. One measure of the scale of change is that it has allowed a million-fold improvement in speed and cost when compared to the first sequencing of the human genome. In 2000, sequencing of one human genome took over 10 years and cost more than a billion dollars: today, the human genome can be sequenced in a single day at a cost of $1,000. More than a million human genomes are sequenced at scale each year, thanks to the technology co-invented by Professors Balasubramanian and Klenerman, meaning we can understand diseases much better and much more quickly.
Professor Sir Shankar Balsubramanian FRS from the Yusuf Hamied Department of Chemistry, Cancer Research UK Cambridge Institute and a Fellow of Trinity College, said: “I am absolutely delighted at being awarded the Millennium Technology Prize jointly with David Klenerman, but it’s not just for us, I’m happy on behalf of everyone who has contributed to this work.”
Professor Sir David Klenerman FMedSci FRS from the Yusuf Hamied Department of Chemistry, and a Fellow of Christ’s College, said: “It’s the first time that we’ve been internationally recognised for developing this technology. The idea came from Cambridge and was developed in Cambridge. It’s now used all over the world, so I’m delighted largely for the team of people who worked on this project and contributed to its success.”
Next-generation sequencing involves fragmenting sample DNA into many small pieces that are immobilized on the surface of a chip and locally amplified. Each fragment is then decoded on the chip, base-by-base, using fluorescently coloured nucleotides added by an enzyme. By detecting the colour-coded nucleotides incorporated at each position on the chip with a fluorescence detector – and repeating this cycle hundreds of times – it is possible to determine the DNA sequence of each fragment.
The collected data is then analysed using computer software to assemble the full DNA sequence from the sequence of all these fragments. The NGS method’s ability to sequence billions of fragments in a parallel fashion makes the technique fast, accurate and cost-efficient. The invention of NGS was a revolutionary approach to the understanding of the genetic code in all living organisms.
Next-generation sequencing provides an effective way to study and identify new coronavirus strains and other pathogens. With the emergence of the COVID-19 pandemic, the technology is now being used to track and explore mutations in the coronavirus. This work has helped the creation of multiple vaccines now being administered worldwide and is critical to the creation of new vaccines against new dangerous viral strains. The results will also be used to prevent future pandemics.
The technology is also allowing scientists and researchers to identify the underlying factors in individuals that contribute to their immune response to COVID-19. This information is essential to unravelling the reason behind why some people respond much worse to the virus than others.
NGS technology has revolutionised global biological and biomedical research and has enabled the development of a broad range of related technologies, applications and innovations. Due to its efficiency, NGS is widely adopted in healthcare and diagnostics, such as cancer, rare diseases, infectious medicine, and sequencing-based non-invasive prenatal testing.
It is increasingly used to define the genetic risk genes for patients with a rare disease and to define new drug targets for disease in defined patient groups. NGS has also contributed to the creation of new and powerful biological therapies like antibodies and gene therapies.
In the field of cancer, NGS is becoming the standard analytical method for defining personalised therapeutic treatment. The technology has dramatically improved our understanding of the genetic basis of many cancers and is often used both for clinical tests for early detection and diagnostics both from tumours and patients’ blood samples.
In addition to medical applications, NGS has also had a major impact on all of biology as it allows the clear identification of thousands of organisms in almost any kind of sample, which is important for agriculture, ecology and biodiversity research.
Academy Professor Päivi Törmä, Chair of the Millennium Technology Prize Selection Committee, said: “The future potential of NGS is enormous and the exploitation of the technology is still in its infancy. The technology will be a crucial element in promoting sustainable development through personalisation of medicine, understanding and fighting killer diseases, and hence improving the quality of life. Professor Balasubramanian and Professor Klenerman are worthy winners of the prize.”
Professor Marja Makarow, Chair of Technology Academy Finland said: “Collaboration is an essential part of ensuring positive change for the future. Next Generation Sequencing is the perfect example of what can be achieved through teamwork and individuals from different scientific backgrounds coming together to solve a problem.
“The technology pioneered by Professor Balasubramanian and Professor Klenerman has also played a key role in helping discover the coronavirus’s sequence, which in turn enabled the creation of the vaccines – itself a triumph for cross-border collaboration – and helped identify new variants of COVID-19.”
On 19 May 2021, Professors Balasubramanian and Klenerman will deliver the Millennium Technology Prize Lecture, talking about their innovation, at 14:30 at the Millennium Innovation Forum. The lecture can be accessed here.
This article was first published on the University of Cambridge website.